Sumitomo Pharma Co., Ltd. (TYO:4506)

Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of JPY 850.99 billion. The enterprise value is 1.08 trillion.

Market Cap	850.99B
Enterprise Value	1.08T

Important Dates

The last earnings date was Friday, October 31, 2025.

Earnings Date	Oct 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Sumitomo Pharma has 397.29 million shares outstanding.

Current Share Class	397.29M
Shares Outstanding	397.29M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.03%
Owned by Institutions (%)	16.33%
Float	180.16M

Valuation Ratios

The trailing PE ratio is 5.50 and the forward PE ratio is 12.05. Sumitomo Pharma's PEG ratio is 0.73.

PE Ratio	5.50
Forward PE	12.05
PS Ratio	1.91
PB Ratio	3.20
P/TBV Ratio	n/a
P/FCF Ratio	36.97
P/OCF Ratio	28.39
PEG Ratio	0.73

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.75, with an EV/FCF ratio of 46.72.

EV / Earnings	6.95
EV / Sales	2.42
EV / EBITDA	7.75
EV / EBIT	9.23
EV / FCF	46.72

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.99.

Current Ratio	1.36
Quick Ratio	0.83
Debt / Equity	0.99
Debt / EBITDA	1.89
Debt / FCF	11.42
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 81.47% and return on invested capital (ROIC) is 14.15%.

Return on Equity (ROE)	81.47%
Return on Assets (ROA)	9.25%
Return on Invested Capital (ROIC)	14.15%
Return on Capital Employed (ROCE)	20.16%
Revenue Per Employee	116.18M
Profits Per Employee	40.38M
Employee Count	3,832
Asset Turnover	0.56
Inventory Turnover	1.81

Taxes

Income Tax	-11.90B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +263.05% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+263.05%
50-Day Moving Average	1,729.82
200-Day Moving Average	1,077.56
Relative Strength Index (RSI)	70.45
Average Volume (20 Days)	6,824,370

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of JPY 445.21 billion and earned 154.72 billion in profits. Earnings per share was 389.45.

Revenue	445.21B
Gross Profit	274.39B
Operating Income	116.80B
Pretax Income	142.82B
Net Income	154.72B
EBITDA	139.15B
EBIT	116.80B
Earnings Per Share (EPS)	389.45

Balance Sheet

The company has 38.49 billion in cash and 262.85 billion in debt, giving a net cash position of -224.36 billion or -564.73 per share.

Cash & Cash Equivalents	38.49B
Total Debt	262.85B
Net Cash	-224.36B
Net Cash Per Share	-564.73
Equity (Book Value)	265.59B
Book Value Per Share	668.50
Working Capital	72.08B

Cash Flow

In the last 12 months, operating cash flow was 29.97 billion and capital expenditures -6.96 billion, giving a free cash flow of 23.02 billion.

Operating Cash Flow	29.97B
Capital Expenditures	-6.96B
Free Cash Flow	23.02B
FCF Per Share	57.94

Margins

Gross margin is 61.63%, with operating and profit margins of 26.23% and 34.75%.

Gross Margin	61.63%
Operating Margin	26.23%
Pretax Margin	32.08%
Profit Margin	34.75%
EBITDA Margin	31.26%
EBIT Margin	26.23%
FCF Margin	5.17%

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.00%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	18.18%
FCF Yield	2.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of 1.84 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.84
Piotroski F-Score	6